RedHill Biopharma (RDHL) Change in Receivables (2016 - 2022)

RedHill Biopharma (RDHL) has 7 years of Change in Receivables data on file, last reported at $1.5 million in Q4 2022.

• Change in Receivables for Q4 2022 came in at $1.5 million, up 190.55% year-over-year; the trailing twelve-month figure through Dec 2022 was $5.7 million (up 82.5% YoY), and the FY2025 annual result was -$2.9 million, down 271.54% from the prior year.
• Change in Receivables climbed to $1.5 million in Q4 2022 per RDHL's latest filing, from -$2.3 million in the prior quarter.
• Over five years, Change in Receivables peaked at $6.1 million in Q3 2020 and troughed at -$16.2 million in Q4 2020.
• A 5-year average of -$248800.0 and a median of -$52500.0 in 2019 frame the typical range for Change in Receivables.
• On a YoY basis, Change in Receivables climbed as much as 5487.27% in 2020 and fell as far as 17367.02% in 2020.
• A 5-year view of Change in Receivables shows it stood at $474000.0 in 2018, then tumbled by 80.17% to $94000.0 in 2019, then plunged by 17367.02% to -$16.2 million in 2020, then jumped by 89.9% to -$1.6 million in 2021, then jumped by 190.55% to $1.5 million in 2022.
• Business Quant data shows RDHL's Change in Receivables at $1.5 million in Q4 2022, -$2.3 million in Q3 2022, and $718000.0 in Q2 2022.